CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Routine Continuous Electrocardiographic Monitoring Following Percutaneous Coronary Interventions Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association Left Main Stenting: What We Have Learnt So Far? Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 Older Adults in the Cardiac Intensive Care Unit: Factoring Geriatric Syndromes in the Management, Prognosis, and Process of Care: A Scientific Statement From the American Heart Association Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction: A Post Hoc Analysis of the Randomized TOTAL Trial An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial

Original ResearchJanuary 2020 Vol 13, Issue 1

JOURNAL:Circ Cardiovasc Interv. Article Link

Routine Continuous Electrocardiographic Monitoring Following Percutaneous Coronary Interventions

MA Al-Hijji , R Gulati,M Singh et al. Keywords: routine electrocardiographic monitoring post PCI; arrhythmia

ABSTRACT


BACKGROUND - The clinical utility of routine electrocardiographic monitoring following percutaneous coronary interventions (PCI) is not well studied.

 

METHODS - We prospectively evaluated the incidence, cost, and the clinical implications of actionable arrhythmia alarms on telemetry monitoring following PCI. One thousand three hundred fifty-eight PCI procedures (989 [72.8%] for acute coronary syndrome and 369 [27.2%] for stable angina) on patients admitted to nonintensive care unit were identified and divided into 2 groups; group 1, patients with actionable alarms (AA) and group 2, patients with non-AA. AA included (1) ≥3 s electrical pause or asystole; (2) high-grade Mobitz type II atrioventricular block or complete heart block; (3) ventricular fibrillation; (4) ventricular tachycardia (>15 beats); (5) atrial fibrillation with rapid ventricular response; (6) supraventricular tachycardia (>15 beats). Primary outcomes were 30-day all-cause mortality. Cost-savings analysis was performed.

 

RESULTS - Incidence of AA was 2.2% (37/1672). Time from end of procedure to AA was 5.5 (0.5, 24.5) hours. Patients with AA were older, presented with acute congestive heart failure or non–ST-segment–elevation myocardial infarction, and had multivessel or left main disease. The 30-day all-cause mortality was significantly higher in patients with AA (6.5% versus 0.3% in non-AA [P<0.001]). Applying the standardized costing approach and tailored monitoring per the American Heart Association guidelines lead to potential cost savings of $622 480.95 for the entire population.

 

CONCLUSIONS - AA following PCI were infrequent but were associated with increase in 30-day mortality. Following American Heart Association guidelines for monitoring after PCI can lead to substantial cost saving.